

Nelson Chao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/825702/publications.pdf>

Version: 2024-02-01

143
papers

3,715
citations

172207

29
h-index

149479

56
g-index

244
all docs

244
docs citations

244
times ranked

5179
citing authors

#	ARTICLE	IF	CITATIONS
1	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	2.5	35
2	Home-Based Hematopoietic Cell Transplantation in the United States. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 207.e1-207.e8.	0.6	3
3	Targeting Glycolysis in Alloreactive T Cells to Prevent Acute Graft-Versus-Host Disease While Preserving Graft-Versus-Leukemia Effect. <i>Frontiers in Immunology</i> , 2022, 13, 751296.	2.2	6
4	Risk Factors for CMV Viremia and Treatment-Associated Adverse Events Among Pediatric Hematopoietic Stem Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab639.	0.4	10
5	Financial incentives to increase stool collection rates for microbiome studies in adult bone marrow transplant patients. <i>PLoS ONE</i> , 2022, 17, e0267974.	1.1	0
6	GVHD – it is all about the microenvironment!. <i>Blood</i> , 2022, 139, 2853-2854.	0.6	0
7	MAIT and V α 2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	19
8	Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 137-143.	1.3	15
9	Assessing the Feasibility of a Novel mHealth App in Hematopoietic Stem Cell Transplant Patients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 181.e1-181.e9.	0.6	18
10	Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study. <i>Blood</i> , 2021, 137, 1527-1537.	0.6	42
11	Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 267.e1-267.e5.	0.6	6
12	Chlorhexidine Gluconate Bathing Reduces the Incidence of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 262.e1-262.e11.	0.6	7
13	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	1.3	6
14	Quantifying Skin Stiffness in Graft-Versus-Host Disease, Morphea, and Systemic Sclerosis Using Acoustic Radiation Force Impulse Imaging and Shear Wave Elastography. <i>Journal of Investigative Dermatology</i> , 2021, 141, 924-927.e2.	0.3	10
15	BAFF promotes heightened BCR responsiveness and manifestations of chronic GVHD after allogeneic stem cell transplantation. <i>Blood</i> , 2021, 137, 2544-2557.	0.6	23
16	Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant. <i>Blood Cancer Journal</i> , 2021, 11, 92.	2.8	2
17	A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant. <i>PLoS ONE</i> , 2021, 16, e0252995.	1.1	3
18	Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 669.e1-669.e8.	0.6	4

#	ARTICLE	IF	CITATIONS
19	Female Sex Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 784.e1-784.e7.	0.6	4
20	The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae. <i>Bone Marrow Transplantation</i> , 2021, 56, 2889-2896.	1.3	8
21	Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, , .	1.3	2
22	Calcium/Calmodulin Dependent Protein Kinase Kinase 2 Regulates the Expansion of Tumor-Induced Myeloid-Derived Suppressor Cells. <i>Frontiers in Immunology</i> , 2021, 12, 754083.	2.2	16
23	Allogeneic Stem Cell Transplantation with Omidubicel: Long-Term Follow-up from a Single Center. <i>Blood</i> , 2021, 138, 1827-1827.	0.6	1
24	The gut microbiota is associated with immune cell dynamics in humans. <i>Nature</i> , 2020, 588, 303-307.	13.7	273
25	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2181-2189.	2.0	51
26	Multi-omics analyses of radiation survivors identify radioprotective microbes and metabolites. <i>Science</i> , 2020, 370, .	6.0	260
27	I have a gut feelingâ€¦. <i>Blood</i> , 2020, 136, 1380-1380.	0.6	0
28	Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality. <i>PLoS ONE</i> , 2020, 15, e0238824.	1.1	4
29	Clinical and Neuroimaging Correlates of Post-Transplant Delirium. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2323-2328.	2.0	0
30	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	1.7	23
31	House calls for stem cell transplant patients during the COVID-19 pandemic. <i>Blood</i> , 2020, 136, 370-371.	0.6	5
32	Microtransplantation in older patients with <scp>AML</scp>: A pilot study of safety, efficacy and immunologic effects. <i>American Journal of Hematology</i> , 2020, 95, 662-671.	2.0	7
33	Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2020, 382, 822-834.	13.9	435
34	Endothelial cell function and endothelialâ€¦related disorders following haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2020, 190, 508-519.	1.2	53
35	The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic CVHD. <i>Blood</i> , 2020, 136, 130-136.	0.6	97
36	Fibrinogen-Coated Albumin Nanospheres Prevent Thrombocytopenia-Related Bleeding. <i>Radiation Research</i> , 2020, 194, 162.	0.7	3

#	ARTICLE	IF	CITATIONS
37	Female Gender Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2020, 136, 18-19.	0.6	0
38	Morphologic Leukemia-Free State in Acute Myeloid Leukemia Is Sufficient for Successful Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2020, 136, 24-25.	0.6	0
39	Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. <i>Transplant Infectious Disease</i> , 2019, 21, e13145.	0.7	22
40	The whole-genome landscape of Burkitt lymphoma subtypes. <i>Blood</i> , 2019, 134, 1598-1607.	0.6	113
41	Biodistribution and sensitive tracking of immune cells with plasmonic gold nanostars. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 3403-3411.	3.3	10
42	CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer. <i>Nature Communications</i> , 2019, 10, 2450.	5.8	72
43	Donor Allospecific CD44 ^{high} Central Memory T Cells Have Decreased Ability to Mediate Graft-vs.-Host Disease. <i>Frontiers in Immunology</i> , 2019, 10, 624.	2.2	14
44	Interrater Reliability of Clinical Grading Measures for Cutaneous Chronic Graft-vs-Host Disease. <i>JAMA Dermatology</i> , 2019, 155, 833.	2.0	6
45	High-dose intravenous immunoglobulin as adjuvant treatment for grade IV acute cutaneous graft-versus-host disease. <i>British Journal of Dermatology</i> , 2019, 181, 869-871.	1.4	4
46	Late effects of total body irradiation on hematopoietic recovery and immune function in rhesus macaques. <i>PLoS ONE</i> , 2019, 14, e0210663.	1.1	20
47	Lactose drives <i>Enterococcus</i> expansion to promote graft-versus-host disease. <i>Science</i> , 2019, 366, 1143-1149.	6.0	217
48	Transplantation without pretransplant therapy: Is this a possibility? Insights into providing transplantation at diagnosis for patients with acute leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 101108.	0.7	0
49	Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade. <i>Cancer Letters</i> , 2019, 440-441, 1-10.	3.2	15
50	Inferior survival after microbiota injury: A multicenter allo-HCT study. <i>Journal of Clinical Oncology</i> , 2019, 37, 7015-7015.	0.8	1
51	Pre-Transplant Hepatic Steatosis (fatty liver) Predicts Chronic Graft-Vs-Host Disease but Does Not Affect Mortality. <i>Blood</i> , 2019, 134, 5731-5731.	0.6	0
52	Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 932-937.	1.3	1
53	Study Limitations in HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia—Reply. <i>JAMA Oncology</i> , 2018, 4, 891.	3.4	2
54	HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia. <i>JAMA Oncology</i> , 2018, 4, 54.	3.4	33

#	ARTICLE	IF	CITATIONS
55	Pediatric Cancer in Northern Tanzania: Evaluation of Diagnosis, Treatment, and Outcomes. <i>Journal of Global Oncology</i> , 2018, 4, 1-10.	0.5	16
56	Novel Cellular Therapeutic Approaches for the Prevention and Management of Graft-Versus-Host Disease. <i>Current Stem Cell Reports</i> , 2018, 4, 318-326.	0.7	0
57	Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 29.	6.9	36
58	SYK inhibitor entospletinib prevents ocular and skin GVHD in mice. <i>JCI Insight</i> , 2018, 3, .	2.3	39
59	Loss of Microbiota Diversity after Autologous Stem Cell Transplant Is Comparable to Injury in Allogeneic Stem Cell Transplant. <i>Blood</i> , 2018, 132, 608-608.	0.6	9
60	Intestinal Enterococcus Is a Major Risk Factor for the Development of Acute Gvhd. <i>Blood</i> , 2018, 132, 358-358.	0.6	4
61	An mHealth Pain Coping Skills Training Intervention for Hematopoietic Stem Cell Transplantation Patients: Development and Pilot Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2018, 6, e66.	1.8	31
62	Calcium/Calmodulin Dependent Protein Kinase Kinase 2 (CaMKK2) Expressed in the Host Promotes Lymphoma Cells Growth By Controlling Myeloid Derived Suppressor Cells Expansion. <i>Blood</i> , 2018, 132, 272-272.	0.6	0
63	Endothelial Cell-Derived Extracellular Vesicles Mitigate Radiation-Induced Hematopoietic Injury. <i>Blood</i> , 2018, 132, 2581-2581.	0.6	0
64	Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma. <i>Hematological Oncology</i> , 2017, 35, 752-759.	0.8	5
65	Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 853-856.	2.0	28
66	Memory T cells: A helpful guard for allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 211-219.	0.6	22
67	An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD. <i>Blood</i> , 2017, 130, 2131-2145.	0.6	37
68	Calcium/calmodulin-dependent kinase kinase 2 regulates hematopoietic stem and progenitor cell regeneration. <i>Cell Death and Disease</i> , 2017, 8, e3076-e3076.	2.7	22
69	Thioredoxin mitigates radiation-induced hematopoietic stem cell injury in mice. <i>Stem Cell Research and Therapy</i> , 2017, 8, 263.	2.4	16
70	Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. <i>Journal of Hematology and Oncology</i> , 2016, 9, 71.	6.9	20
71	Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity. <i>Advances in Radiation Oncology</i> , 2016, 1, 272-280.	0.6	10
72	Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial. <i>Clinical Infectious Diseases</i> , 2016, 63, 999-1006.	2.9	63

#	ARTICLE	IF	CITATIONS
73	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. <i>Blood</i> , 2015, 125, 4085-4094.	0.6	101
74	Hematopoietic Stem Cell Transplantation for CD40 Ligand Deficiency: Single Institution Experience. <i>Pediatric Blood and Cancer</i> , 2015, 62, 2216-2222.	0.8	19
75	Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1776-1782.	2.0	13
76	Differential Requirements of TCR Signaling in Homeostatic Maintenance and Function of Dendritic Epidermal T Cells. <i>Journal of Immunology</i> , 2015, 195, 4282-4291.	0.4	46
77	Are We Ready for a Radiological Terrorist Attack Yet? Report From the Centers for Medical Countermeasures Against Radiation Network. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 504-505.	0.4	17
78	Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 266-274.	2.0	331
79	Verification of a novel method for tube voltage constancy measurement of orthovoltage x-ray irradiators. <i>Medical Physics</i> , 2014, 41, 084101.	1.6	0
80	Toward an organ based dose prescription method for the improved accuracy of murine dose in orthovoltage x-ray irradiators. <i>Medical Physics</i> , 2014, 41, 034101.	1.6	15
81	Reduced-Intensity Allogeneic Transplantation Using Alemtuzumab from HLA-Matched Related, Unrelated, or Haploidentical Related Donors for Patients with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 257-263.	2.0	15
82	Allotransplantation for Patients Age \leq 40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 960-968.	2.0	37
83	Increased BCR responsiveness in B cells from patients with chronic GVHD. <i>Blood</i> , 2014, 123, 2108-2115.	0.6	86
84	A Translatable Predictor of Human Radiation Exposure. <i>PLoS ONE</i> , 2014, 9, e107897.	1.1	51
85	Blazing a new TRAIL in hematopoietic cell transplantation. <i>Journal of Clinical Investigation</i> , 2013, 123, 2362-2363.	3.9	0
86	You Cannot Improve What You Do Not Measure. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1467-1468.	2.0	0
87	Surgical Mask Usage Reduces the Incidence of Parainfluenza Virus 3 in Recipients of Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 462-462.	0.6	3
88	High Dose BCNU/Melphalan Preparative Regimen Doubles Event Free Survival of Myeloma Patients Undergoing Autologous Transplantation. <i>Blood</i> , 2011, 118, 2012-2012.	0.6	1
89	Chemo-Mobilization Provides Superior Mobilization and Collection in Autologous Stem Cell Transplants but with Less Predictability and At a Higher Cost. <i>Blood</i> , 2011, 118, 4048-4048.	0.6	6
90	Impact of High Dose Cyclophosphamide on the Outcome of Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2011, 118, 4127-4127.	0.6	9

#	ARTICLE	IF	CITATIONS
91	The Impact of Lymphocyte Subset Recovery At 3 Months on Progression-Free Survival After Myeloablative Allogeneic Stem Cell Transplantation,. Blood, 2011, 118, 4065-4065.	0.6	0
92	Differences in Stem Cell Collection Practices and Related Outcomes Between Centers That Conduct and Do Not Conduct Aphaeresis on Weekends. Blood, 2011, 118, 1925-1925.	0.6	0
93	A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2011, 118, 5129-5129.	0.6	0
94	Pleiotrophin Signaling Is Necessary and Sufficient for Hematopoietic Stem Cell Self-Renewal In Vivo. Blood, 2010, 116, 404-404.	0.6	1
95	Allogeneic Effector Memory T Cells Enhance Hematopoietic Engraftment and Immune Reconstitution After Stem Cell Transplantation. Blood, 2010, 116, 78-78.	0.6	1
96	Hematopoietic Stem Cell Transplantation Across Genetic Barriers Using a Nonmyeloablative Conditioning Regimen. , 2010, , 119-162.		0
97	VE Cadherin Positive Endothelial Cells Regulate Hematopoietic Reconstitution In Vivo.. Blood, 2010, 116, 3734-3734.	0.6	0
98	Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350cGy) and Fludarabine Conditioning. Blood, 2010, 116, 3523-3523.	0.6	0
99	Risk-Factors for Acute Graft-Versus-Host Disease and Survival After Hematopoietic Cell Transplantation From Siblings and Unrelated Donors " An Analysis of the CIBMTR. Blood, 2010, 116, 897-897.	0.6	0
100	Facilitation of Hematopoietic Reconstitution Via Inhibition of Bone Marrow Endothelial Cell-Mediated SDF-1 Signaling.. Blood, 2010, 116, 3859-3859.	0.6	0
101	Prospective, Biological Randomized Study of T-Cell Depleted Nonmyeloablative Allogeneic Transplantation From HLA-Matched Related, Unrelated or Haploidentical Donors for Patients with Hematologic Malignancies. Blood, 2010, 116, 3541-3541.	0.6	0
102	An Ear-Tissue Model for High-Resolution In Vivo Imaging.. Blood, 2010, 116, 1456-1456.	0.6	0
103	A Comprehensive Comparison Immune Recovery In Adult Patients Following Allogeneic Umbilical Cord Blood, Matched Sibling and Matched Unrelated Donor Stem Cell Transplantation. Blood, 2010, 116, 2313-2313.	0.6	0
104	Plerixafor (Mozobil®) Selectively Enhances Donor Hematopoietic Cell Engraftment.. Blood, 2009, 114, 368-368.	0.6	2
105	A Prospective Study of Donor ImmuKnow® as a Biomarker for Acute GvHD in Hematopoietic Cell Transplantation Recipients.. Blood, 2009, 114, 4646-4646.	0.6	0
106	Allospecific Effector Memory T Cells Are Able to Mediate Second-Set Skin Graft Rejection but Unable to Induce Graft-Versus-Host Disease.. Blood, 2009, 114, 232-232.	0.6	0
107	Deletion of Bak and Bax in Tie2+ BM Hematopoietic Stem Cells Induces a B Cell Lymphoproliferative Disorder.. Blood, 2009, 114, 1247-1247.	0.6	0
108	Memory T Cells. Biology of Blood and Marrow Transplantation, 2008, 14, 17-22.	2.0	12

#	ARTICLE	IF	CITATIONS
109	What Do You Do with the "Pink Sheets"? Hematology American Society of Hematology Education Program, 2008, 2008, 23-25.	0.9	2
110	Differential Impact of Inhibitory and Activating Killer Ig-Like Receptors and HLA Ligand on Outcomes of Transplantation for Myeloid and Lymphoid Malignancies.. Blood, 2008, 112, 3255-3255.	0.6	5
111	Safety Trial of NK Cell Enhanced Donor Lymphocyte Infusions from a 3-5/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation. Blood, 2008, 112, 342-342.	0.6	1
112	Total Body Irradiation 1350cGy/Fludarabine (TBI/FLU) vs Myeloablative Busulfan/Fludarabine (Bu/Flu) Preparation in Adult Recipients of Dual Umbilical Cord Blood (UCB) Transplantation: Superior Engraftment with Low Treatment-Related Mortality. Blood, 2008, 112, 4403-4403.	0.6	0
113	Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma.. Blood, 2008, 112, 3325-3325.	0.6	0
114	Pleiotrophin Is a Growth Factor for Hematopoietic Stem Cells and Induces Stem Cell Self-Renewal. Blood, 2008, 112, 78-78.	0.6	1
115	Insulin-Like Growth Factor 1 Protects against Lethal Irradiation. Blood, 2008, 112, 3488-3488.	0.6	14
116	Early Pre/Post Fluoro-Deoxyglucose Positive Emission Tomography (PET) Does Not Predict Outcome of Patients Undergoing Hematopoietic Stem Cell Transplantation in Hodgkins Disease and Non-Hodgkins Lymphoma.. Blood, 2008, 112, 2180-2180.	0.6	0
117	Allogeneic Committed Hematopoietic Progenitors Are Protective Against Radiation.. Blood, 2007, 110, 4871-4871.	0.6	0
118	Endothelial Progenitor Cell Transplantation for Hematopoietic Regeneration.. Blood, 2007, 110, 179-179.	0.6	0
119	Myeloablative Intravenous Busulfan/Fludarabine Conditioning Does Not Facilitate Reliable Engraftment of Dual Umbilical Cord Blood Grafts in Adult Recipients.. Blood, 2007, 110, 2007-2007.	0.6	1
120	Treatment of Established Graft-Versus-Host Disease by PG490-88.. Blood, 2007, 110, 3243-3243.	0.6	0
121	Identification of Pleiotrophin as a Novel Growth Factor for Hematopoietic Stem and Progenitor Cells.. Blood, 2007, 110, 1404-1404.	0.6	0
122	Prevention of Graft-Versus-Host Disease in Mouse Model Using Anti-Mouse C5 Antibody.. Blood, 2007, 110, 3245-3245.	0.6	10
123	Prophylaxis and Treatment of Acute Graft-Versus-Host Disease. Seminars in Hematology, 2006, 43, 32-41.	1.8	58
124	Adult Umbilical Cord Blood Transplantation Following Non-Myeloablative Conditioning; Impact of Increased Cell Dose and 200cGy TBI on Engraftment and Survival.. Blood, 2006, 108, 5399-5399.	0.6	1
125	Prevention of Graft-Versus-Host Disease by Selective Depletion of Alloreactive T Cells.. Blood, 2006, 108, 3174-3174.	0.6	0
126	In Vivo Radioprotective Effects of Growth Hormone.. Blood, 2006, 108, 5158-5158.	0.6	0

#	ARTICLE	IF	CITATIONS
127	A Pilot Trial of Two Dose Levels of Rabbit Antithymocyte Globulin, (rATG), Thymoglobulin, as Part of a Myeloablative-Conditioning for a HLA Identical Matched Related Donor Stem Cell Transplant (SCT) with Cyclosporine (CsA) as Graft Versus Host Disease (GvHD) Prophylaxis.. Blood, 2006, 108, 5369-5369.	0.6	0
128	The Retinoid X Receptor Regulates Human Hematopoietic Stem Cell Fate.. Blood, 2006, 108, 1324-1324.	0.6	0
129	A Prospective Study of Bortezomib in Combination with Melphalan and Prednisone for Patients with Previously Untreated Multiple Myeloma.. Blood, 2005, 106, 5181-5181.	0.6	1
130	Partially HLA Matched, Non-Myeloablative Allogeneic Transplantation.. Blood, 2005, 106, 2896-2896.	0.6	5
131	Multimodal Dose Dense Therapy for Mantle Cell Lymphoma.. Blood, 2005, 106, 5501-5501.	0.6	0
132	Blocking Complement-Mediated Hemolysis Using RNA Aptamers That Bind Complement Component C8.. Blood, 2005, 106, 186-186.	0.6	0
133	Concomitant Induction of CMVpp65-Specific CD4+ and CD8+ T Cells Using Dendritic Cells Transfected with mRNA Encoding an Invariant Chain-pp65 Fusion Protein.. Blood, 2005, 106, 3243-3243.	0.6	0
134	Phase I Study of Gemcitabine, Fludarabine and Mitoxantrone for Relapsed or Refractory Leukemia.. Blood, 2005, 106, 4623-4623.	0.6	0
135	Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens. Biology of Blood and Marrow Transplantation, 2004, 10, 569-575.	2.0	51
136	Transfer of allogeneic CD62L ^{hi} memory T cells without graft-versus-host disease. Blood, 2004, 103, 1534-1541.	0.6	247
137	Campath-1H May Have Activity in the Treatment of Multiple Myeloma.. Blood, 2004, 104, 4931-4931.	0.6	1
138	Promotion of Stem Cell-Derived New T Cell Generation by CD62L ^{hi} Memory T Cells Requires Alloantigen Recognition.. Blood, 2004, 104, 3041-3041.	0.6	0
139	Human Memory T Cells Proliferate but Do Not Elicit Cytotoxicity in Response to Alloantigens.. Blood, 2004, 104, 1229-1229.	0.6	2
140	Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells. Biology of Blood and Marrow Transplantation, 2002, 8, 249-256.	2.0	46
141	Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 2001, 7, 343-351.	2.0	64
142	Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen. Blood, 2001, 98, 3486-3488.	0.6	53
143	Graft-versus-host disease: the viewpoint from the donor T cell. Biology of Blood and Marrow Transplantation, 1997, 3, 1-10.	2.0	40